VDYNE's Clinical Trial Addresses Critical Medical Needs
On 2 April 2026, VDYNE, Inc., a medical device company headquartered in Maple Grove, Minnesota, announced that the U.S. Food & Drug Administration (FDA) approved an investigational device exemption (IDE) for its Transcatheter Tricuspid Valve Replacement (TTVR) system. This approval allows the company to initiate a pivotal clinical trial in the United States to evaluate the safety and effectiveness of its TTVR system in patients with severe tricuspid regurgitation (TR).
“This is a defining milestone for VDYNE and an important step toward bringing a much-needed therapy to patients with severe tricuspid regurgitation,” stated Mike Buck, Chief Executive Officer of VDYNE.
Currently, severe tricuspid regurgitation impacts 1.5 million people in the U.S., but a small per cent of these patients qualify for surgical treatment. The condition is associated with a 10 per cent mortality rate within one year, highlighting the urgent need for alternative treatment options.
The pivotal study will be conducted at leading clinical centres across the United States. VDYNE’s TTVR system is designed to provide a minimally invasive, patient-tailored solution that addresses the complexities of tricuspid valve anatomy and disease. Since its first use in humans in November 2023, the system has been utilised globally through clinical studies and compassionate use. This has provided valuable insights into procedural performance and clinical outcomes.
Innovative Solutions for Tricuspid Regurgitation
Tricuspid regurgitation occurs when the tricuspid valve does not close properly, allowing blood to flow backward into the right atrium. This can lead to symptoms such as fatigue and fluid retention, significantly affecting patients’ quality of life.
Following the IDE approval, VDYNE is committed to disciplined clinical execution. The company aims to partner with leading investigators to generate high-quality data that will advance the field and improve patient care. The VDYNE TTVR system is still under clinical investigation and is not yet commercially available in the United States or any other country.
Last updated: 4 April 2026, 7:56 pm
